R. K. Kandane-Rathnayake BBiomedSci (Hons), PhD; J. P. Isbister MBBS (Hons), FRACP, FRCPA; A. J. Zatta BSc (Hons), PhD; N. J. Aoki BSc, MScMed (Infn Imm); P. Cameron MBBS, MD, FACEM; L. E. Philips BSc (Hons), MPH, PhD.
Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding
Article first published online: 4 OCT 2012
© 2012 The Authors. ANZ Journal of Surgery © 2012 Royal Australasian College of Surgeons
ANZ Journal of Surgery
Volume 83, Issue 3, pages 155–160, March 2013
How to Cite
Kandane-Rathnayake, R. K., Isbister, J. P., Zatta, A. J., Aoki, N. J., Cameron, P., Phillips, L. E., on behalf of the Australian and New Zealand Haemostasis Registry Steering Committee (2013), Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding. ANZ Journal of Surgery, 83: 155–160. doi: 10.1111/j.1445-2197.2012.06285.x
- Issue published online: 6 MAR 2013
- Article first published online: 4 OCT 2012
- Manuscript Accepted: 23 AUG 2012
- blood transfusion;
- Jehovah's Witness;
- recombinant FVIIa;
The Australian and New Zealand Haemostasis Registry (ANZHR) included patients who received off-licence recombinant activated factor VII (rFVIIa) for critical bleeding from 2000 to 2009. Approximately 1.3% of the ANZHR patients were Jehovah's Witnesses (JWs). We compared them with the non-JW patients in the registry.
Patient characteristics (e.g. gender, context of bleeding), factors influencing rFVIIa use (e.g. body temperature and pH) and outcomes (e.g. bleeding response (stopped/attenuated or unchanged) to rFVIIa, mortality) were compared between JW and non-JW patients using Fisher's exact chi-square tests and Kruskal-Wallis tests.
A total of 42 JW and 3134 non-JW patients were included in the analysis. Approximately 99% (n = 3098) of non-JWs received blood products compared with only 30% (n = 13) of JWs (P < 0.01). The distribution of gender and contexts of critical bleeding in the two groups was significantly different. Approximately 17% of the non-JW patients were hypothermic (T < 35°C) and about 19% were acidotic (pH < 7.2) at the time of initial rFVIIa administration. Conversely, none of the JWs were hypothermic and only one was acidotic. The proportion of positive responders to rFVIIa (stopped/attenuated bleeding following rFVIIa use) was similar in both groups (75% non-JWs, 74% JWs; P = 1.0). Approximately 28% of non-JW and 17% of JW patients were deceased by day 28 following rFVIIa use (P = 0.16).
Several factors were observed to be significantly different between JW and non-JW patients, yet the proportions of responders to rFVIIa were similar in both groups. The actual factors influencing response to rFVIIa are yet to be determined.